UA138151U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination and radiography. Additionally, in the patient's serum determine the polymorphism of the nitric oxide synthase gene (eNOS T786C), the content of thrombomodulin, folic acid, oxyproline, C-reactive protein (SRP), interleukin 6 (IL-6) and at homozygous C-level. 5 ng / ml, folic acid <6 ng / ml, oxyproline> 15 μmol / l, PSA> 6 mg / l, IL-6> 10 ng / l predict the development of osteoarthritis.

Description

A useful model belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in the diagnosis of the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include radiography, examination of a biopsy of the synovial membrane, synovial fluid, a biopsy of cartilage (Okorokov

A.N. Diagnosis of diseases of internal organs. - M., 2001. - T. 2. - E. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to clinical examination and radiography, according to a useful model, the polymorphism of the nitric oxide synthase gene (eMmO5 17860), the content of thrombomodulin, folic acid, oxyprolin, C-reactive protein (CRP), interleukin is determined in the patient's blood serum b (1L-6) and with homozygous carrier 786-SS, levels of thrombomodulin 25 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP"b mg/l, IL- 6210 ng/l predict the development osteoarthritis

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the eMO5 1786C gene polymorphism is determined, the content of thrombomodulin, folic acid, oxyproline, SRP, IL-b6 is determined by the immunoenzymatic method. With homozygous carrier 786-SS and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP "6 mg/l,

IL-6 210 ng/l predict the development of osteoarthritis.

A specific example of using the method

Patient R., 65 years old, was hospitalized in the clinic due to pain syndrome in the right knee joint. Examined, x-ray taken. No signs of osteoarthritis were found. Polymorphism of the eMOo5 1786C gene was determined in blood serum, and the content of thrombomodulin, folic acid, oxyproline, SRP, IL-6 was determined by the immunoenzymatic method. A homozygous carrier of 786-SS was established, the levels of thrombomodulin - 11 ng/ml, folic acid - 3.3 ng/ml, oxyproline - 27 μmol/l, SRP - 16 mg/l, IL-6-25 ng/l. The development of osteoarthritis was diagnosed. After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the nitric oxide synthase gene (6ЕМО5 T786С), the content of thrombomodulin, folic acid, oxyproline, C-reactive protein (CRP), interleukin is additionally determined in the patient's blood serum 6 (IL-6) and with homozygous carrier 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, oxyproline "15 μmol/l, SRP "b mg/l, IL-6 »10 ng/l predict the development of osteoarthritis.